Vietnam Clinical Trials Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

The Vietnam clinical trials market was valued at USD 29.84 Million in 2025 and is expected to grow at a CAGR of 6.18%, reaching USD 54.35 Million by 2035. The market is experiencing growth due to increasing participation in global clinical studies and improved healthcare infrastructure.

Q1 2026 Market Updates

The Vietnam clinical trials market was valued at approximately USD 28.10 million in 2024 and is projected to reach USD 51.18 million by 2034, growing at a CAGR of 6.18%. The market has been expanding due to increasing participation in global clinical studies, improved healthcare infrastructure, and growing CRO investments. In 2024, IQVIA invested approximately USD 6 million to launch its AI-powered patient recruitment platform in Vietnam, while Covance opened a new 50,000-square-foot research facility in Hanoi with an USD 8 million investment, increasing capacity by 30%. Vietnam health allocation in 2025 rose significantly to 5.7 trillion VND, representing 3.7% of the total budget, signaling stronger government commitment to healthcare development.

The Iran-US-Israel conflict in early 2026 has disrupted global clinical trial supply chains with implications for Vietnam emerging market. Clinical trial drug shipments are among the most affected categories, as the Strait of Hormuz closure has reduced commercial shipping activity by 90% below pre-war levels and Gulf air-cargo capacity dropped 79% in early March. The Gulf region serves as a critical pharmaceutical transit hub where drugs and ingredients from India, Europe, and China routinely pass before distribution to Asia and other regions. Approximately 80% of the region USD 23.7 billion pharmaceutical industry depends on medicines or ingredients transiting through these disrupted corridors. For Vietnam, where clinical trials rely heavily on imported investigational drugs and specialized reagents, these supply chain bottlenecks risk delaying trial timelines and increasing operational costs for sponsors and CROs.

Despite the disruption, Vietnam clinical trials market is positioned to benefit from the broader reshuffling of global trial site selection. As Gulf countries face severe logistics challenges threatening their growing clinical trial programs, pharmaceutical companies are diversifying trial locations toward Southeast Asian markets with more resilient supply chains. Vietnam competitive advantages, including a large treatment-naive patient population, competitive costs, and expanding CRO infrastructure, make it an attractive alternative. However, the country must address its lengthy approval timeline, averaging 18 months compared to faster processes in Singapore and Malaysia, to fully capitalize on this opportunity. Companies are adapting by establishing alternative drug supply routes that bypass Middle Eastern transit hubs and building local warehousing capacity for investigational products.

Key Takeaways

Government: Vietnam Ministry of Health is working to streamline the clinical trial approval process, which currently averages 18 months, to attract pharmaceutical companies redirecting trials away from conflict-affected Gulf region sites. The government increased health allocation to 5.7 trillion VND in 2025, with a portion directed toward building clinical research infrastructure that supports Vietnam competitiveness as a global trial destination amid shifting geopolitical dynamics. New regulatory guidelines are being developed to facilitate emergency supply routes for investigational drugs, allowing clinical trial sponsors to use alternative import channels when primary logistics corridors through the Middle East are disrupted.

Market: The Vietnam clinical trials market, valued at USD 28.10 million in 2024 with a 6.18% CAGR forecast through 2034, could see accelerated growth as pharmaceutical sponsors diversify trial sites away from disrupted Gulf region locations. Major CROs including IQVIA and Covance have made significant investments in Vietnam clinical research infrastructure during 2024, positioning the country to absorb redirected trial activity as Middle Eastern logistics hubs face prolonged disruption. Clinical trial operational costs in Vietnam are rising modestly as alternative drug supply routes bypassing the Strait of Hormuz add logistics complexity, though the country remains cost-competitive relative to established Asian trial markets.

Procurement: Procurement of investigational medicinal products for Vietnam-based clinical trials faces extended lead times as pharmaceutical shipments reroute around the disrupted Strait of Hormuz and Gulf air-cargo hubs, adding 10-14 days to standard delivery schedules. Clinical trial supply chain managers are establishing regional warehousing in Vietnam for investigational drugs and laboratory reagents, reducing dependence on just-in-time delivery models vulnerable to geopolitical shipping disruptions. Cold-chain logistics procurement for biologics-based clinical trials has become more complex and costly, with specialized air freight capacity reduced by 79% in the Gulf region, forcing sponsors to secure alternative temperature-controlled transport corridors through East Asian routes.